Homology Medicines (FIXX) Posts Earnings Results, Misses Expectations By $0.07 EPS

Homology Medicines (NASDAQ:FIXX) released its quarterly earnings data on Tuesday. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.07), MarketWatch Earnings reports. The company had revenue of $0.98 million during the quarter.

FIXX traded down $0.96 during mid-day trading on Wednesday, reaching $25.03. 15,734 shares of the company traded hands, compared to its average volume of 135,619. Homology Medicines has a 52-week low of $15.07 and a 52-week high of $31.80.

A hedge fund recently raised its stake in Homology Medicines stock. Geode Capital Management LLC lifted its stake in Homology Medicines Inc (NASDAQ:FIXX) by 37.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,033 shares of the company’s stock after purchasing an additional 41,972 shares during the period. Geode Capital Management LLC owned 0.41% of Homology Medicines worth $3,421,000 at the end of the most recent reporting period. 55.64% of the stock is currently owned by institutional investors.



Several equities analysts recently issued reports on FIXX shares. ValuEngine raised Homology Medicines from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. HC Wainwright initiated coverage on shares of Homology Medicines in a research note on Wednesday, February 20th. They set a “buy” rating and a $36.00 target price for the company. Canaccord Genuity initiated coverage on shares of Homology Medicines in a research note on Monday, January 7th. They set a “buy” rating and a $37.00 target price for the company. Finally, Zacks Investment Research lowered shares of Homology Medicines from a “hold” rating to a “sell” rating in a research note on Thursday, January 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $28.93.

WARNING: “Homology Medicines (FIXX) Posts Earnings Results, Misses Expectations By $0.07 EPS” was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://dakotafinancialnews.com/2019/03/13/homology-medicines-fixx-posts-earnings-results-misses-expectations-by-0-07-eps.html.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Featured Article: Call Option

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.